The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Targeting cell-cycle machinery in cancer
Open accessAbstract
SUMMARY Abnormal activity of the core cell-cycle machinery is seen in essentially all tumor types and represents a driving force of tumorigenesis. Recent studies revealed that cell-cycle proteins regulate a wide range of cellular functions, in addition to promoting cell division. With the clinical success of CDK4/6 inhibitors, it is becoming increasingly clear that targeting individual cell-cycle components may represent an effective anti-cancer strategy. Here, we discuss the potential of inhibiting different cell-cycle proteins for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., Campone, M., Hamilton, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,022
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 855
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 663
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Cyclin A in cell cycle control and cancer
Yam, C. H., Fung, T. K., & Poon, R. Y. C. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8510-y · Cited by 520
Cyclin E in normal and neoplastic cell cycles
Hwang, H. C., & Clurman, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208613 · Cited by 514
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 429
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1607-3 · Cited by 427
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells
Singer, J. D., Gurian-West, M., Clurman, B., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.18.2375 · Cited by 404
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Diril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., Tessarollo, L., & Kaldis, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115201109 · Cited by 385
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B. M., et al. (2014) · Nature · doi:10.1038/nature13079 · Cited by 361
Self-citationUbiquitin signaling in cell cycle control and tumorigenesis
Dang, F., Nie, L., & Wei, W. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00648-0 · Cited by 348
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
Self-citationThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Requirement for cyclin D3 in lymphocyte development and T cell leukemias
Sicinska, E., Aifantis, I., Le Cam, L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 340
Self-citationScaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases
Wang, Y., & Prives, C. (1995) · Nature · doi:10.1038/376088a0 · Cited by 336
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M. B., AOCS Study Group, et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1564 · Cited by 302
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Gao, J. J., Cheng, J., Bloomquist, E., Sanchez, J., Wedam, S. B., Singh, H., Amiri-Kordestani, L., Ibrahim, A., Sridhara, R., Goldberg, K. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30804-6 · Cited by 289
Cidado, J., Boiko, S., Proia, T., Ferguson, D., Criscione, S. W., San Martin, M., Pop-Damkov, P., Su, N., Roamio Franklin, V. N., Sekhar Reddy Chilamakuri, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1853 · Cited by 288
The Processivity of Multiubiquitination by the APC Determines the Order of Substrate Degradation
Rape, M., Reddy, S. K., & Kirschner, M. W. (2006) · Cell · doi:10.1016/j.cell.2005.10.032 · Cited by 280
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272
Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerra, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30642-2 · Cited by 261
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Campaner, S., Doni, M., Hydbring, P., Verrecchia, A., Bianchi, L., Sardella, D., Schleker, T., Perna, D., Tronnersjö, S., Murga, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2004 · Cited by 251
Hafner, M., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.05.005 · Cited by 250
Induction of Mammary Gland Hyperplasia and Carcinomas in Transgenic Mice Expressing Human Cyclin E
Bortner, D. M., & Rosenberg, M. P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.453 · Cited by 245
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236
Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C.-S., Barriga, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1425 · Cited by 227
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H. R., Lilischkis, R., Hein, N., Wu, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900121106 · Cited by 225
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 220
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
Kalaszczynska, I., Geng, Y., Iino, T., Mizuno, S.-I., Choi, Y., Kondratiuk, I., Silver, D. P., Wolgemuth, D. J., Akashi, K., & Sicinski, P. (2009) · Cell · doi:10.1016/j.cell.2009.04.062 · Cited by 215
Self-citationA Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
Montagnoli, A., Valsasina, B., Croci, V., Menichincheri, M., Rainoldi, S., Marchesi, V., Tibolla, M., Tenca, P., Brotherton, D., Albanese, C., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.90 · Cited by 206
Finn, R. S., Liu, Y., Zhu, Z., Martin, M., Rugo, H. S., Diéras, V., Im, S.-A., Gelmon, K. A., Harbeck, N., Lu, D. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0751 · Cited by 201
A Centrosomal Localization Signal in Cyclin E Required for Cdk2-Independent S Phase Entry
Matsumoto, Y., & Maller, J. L. (2004) · Science · doi:10.1126/science.1103544 · Cited by 200
CDK7 inhibitors as anticancer drugs
Sava, G. P., Fan, H., Coombes, R. C., Buluwela, L., & Ali, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09885-8 · Cited by 200
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199
Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms
Porter, D. C., Zhang, N., Danes, C., McGahren, M. J., Harwell, R. M., Faruki, S., & Keyomarsi, K. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6254-6269.2001 · Cited by 194
Kinase-independent function of cyclin E
Geng, Y., Lee, Y.-M., Welcker, M., Swanger, J., Zagozdzon, A., Winer, J. D., Roberts, J. M., Kaldis, P., Clurman, B. E., & Sicinski, P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.029 · Cited by 187
Self-citationBayard, Q., Meunier, L., Péneau, C., Renault, V., Shinde, J., Nault, J., Mami, I., Couchy, G., Amaddeo, G., Tubacher, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07552-9 · Cited by 181
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 180
Martínez-Alonso, D., & Malumbres, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.009 · Cited by 179
Cyclin B2 and p53 control proper timing of centrosome separation
Nam, H.-J., & van Deursen, J. M. (2014) · Nature Cell Biology · doi:10.1038/ncb2952 · Cited by 178
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901418106 · Cited by 167
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, C., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 163
The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Ali, S., Heathcote, D. A., Kroll, S. H. B., Jogalekar, A. S., Scheiper, B., Patel, H., Brackow, J., Siwicka, A., Fuchter, M. J., Periyasamy, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0301 · Cited by 161
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype
Olson, C. M., Liang, Y., Leggett, A., Park, W. D., Li, L., Mills, C. E., Elsarrag, S. Z., Ficarro, S. B., Zhang, T., Düster, R., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.012 · Cited by 161
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A. M., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 159
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 156
Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells
Montagnoli, A., Tenca, P., Sola, F., Carpani, D., Brotherton, D. H., Albanese, C., & Santocanale, C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1547 · Cited by 154
Kang, J., Sergio, C. M., Sutherland, R. L., & Musgrove, E. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-32 · Cited by 152
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Patel, H., Periyasamy, M., Sava, G. P., Bondke, A., Slafer, B. W., Kroll, S. H. B., Barbazanges, M., Starkey, R., Ottaviani, S., Harrod, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0847 · Cited by 148
A novel function for Cyclin A2: Control of cell invasion via RhoA signaling
Arsic, N., Bendris, N., Peter, M., Begon‐Pescia, C., Rebouissou, C., Gadéa, G., Bouquier, N., Bibeau, F., Lemmers, B., & Blanchard, J. M. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201102085 · Cited by 138
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Nemunaitis, J. J., Small, K. A., Kirschmeier, P. T., Zhang, D., Zhu, Y., Jou, Y., Statkevich, P., Yao, S., & Bannerji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-259 · Cited by 134
Bonte, D., Lindvall, C. J., Liu, H., Dykema, K. J., Furge, K., & Weinreich, M. (2008) · Neoplasia · doi:10.1593/neo.08216 · Cited by 131
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30616-3 · Cited by 125
Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.
Gopinathan, L., Tan, S. L. W., Padmakumar, V. C., Coppola, V., Tessarollo, L., & Kaldis, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3440 · Cited by 123
Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
Montagnoli, A., Moll, J. K., & Colotta, F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0185 · Cited by 122
Etemadmoghadam, D., Au‐Yeung, G., Wall, M., Mitchell, T. J., Kansara, M., Loehrer, E. A., Batzios, C., George, J., Ftouni, S., Weir, B. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1337 · Cited by 120
Foxp3 Protein Stability Is Regulated by Cyclin-dependent Kinase 2*
Morawski, P. A., Mehra, P., Chen, C., Bhatti, T. R., & Wells, A. D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467704 · Cited by 120
Sonntag, R., Giebeler, N., Nevzorova, Y. A., Bangen, J., Fahrenkamp, D., Lambertz, D., Haas, U., Hu, W., Gaßler, N., Cubero, F. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807155115 · Cited by 107
Etemadmoghadam, D., George, J., Cowin, P. A., Cullinane, C. M., Kansara, M., Chenevix‐Trench, G., Gorringe, K. L., Smyth, G. K., & Bowtell, D. D. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015498 · Cited by 106
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor
Suzuki, T., Urano, T., Miki, Y., Moriya, T., Akahira, J., Ishida, T., Horie, K., Inoue, S., & Sasano, H. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00444.x · Cited by 104
Fassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 102
Stephenson, J., Nemunaitis, J. J., Joy, A. A., Martin, J., Jou, Y., Zhang, D., Statkevich, P., Yao, S., Zhu, Y., Zhou, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.020 · Cited by 101
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Yang, L., Fang, D., Chen, H., Lu, Y.-Y., Dong, Z., Ding, H., Jing, Q., Su, S., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4600 · Cited by 100
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
Wang, J., Yang, T., Xu, G., Liu, H., Ren, C., Xie, W., & Wang, M. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.007 · Cited by 94
De Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells
Sweeney, K. J. E., Swarbrick, A., Sutherland, R. L., & Musgrove, E. A. (1998) · Oncogene · doi:10.1038/sj.onc.1201814 · Cited by 93
Lucenay, K. S., Doostan, I., Karakaş, C., Bui, T. N., Ding, Z., Mills, G. B., Hunt, K. K., & Keyomarsi, K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1646 · Cited by 93
Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer
Egloff, A. M., Vella, L. A., & Finn, O. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3389 · Cited by 91
Ghia, P., Scarfò, L., Perez, S., Pathiraja, K., Derosier, M., Small, K. A., Sisk, C. M., & Patton, N. W. (2017) · Blood · doi:10.1182/blood-2016-10-748210 · Cited by 91
ATRX is a regulator of therapy induced senescence in human cells
Kovatcheva, M., Liao, W., Klein, M. E., Robine, N., Geiger, H., Crago, A. M., Dickson, M. A., Tap, W. D., Singer, S., & Koff, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00540-5 · Cited by 89
Development of CDK2 and CDK5 Dual Degrader TMX‐2172
Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004087 · Cited by 89
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 88
Discovery of XL413, a potent and selective CDC7 inhibitor
Koltun, E. S., Tsuhako, A. L., Brown, D. S., Aay, N., Arcalas, A., Chan, V., Du, H., Engst, S., Ferguson, K., Franzini, M., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.024 · Cited by 87
Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation
Kanakkanthara, A., Jeganathan, K. B., Limzerwala, J. F., Baker, D. J., Hamada, M., Nam, H.-J., van Deursen, W. H., Hamada, N., Naylor, R. M., Becker, N. A., et al. (2016) · Science · doi:10.1126/science.aaf7463 · Cited by 87
Aaltomaa, S. H., Lipponen, P., Ala‐Opas, M., ESKELINEN, M., Syrjänen, K. J., & Kosma, V.-M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690634 · Cited by 85
E- and A-type cyclins as markers for cancer diagnosis and prognosis
Yasmeen, A., Berdel, W. E., Serve, H. L., & Müller‐Tidow, C. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.5.617 · Cited by 83
Horiuchi, D., Huskey, N. E., Kusdra, L., Wohlbold, L., Merrick, K. A., Zhang, C., Creasman, K. J., Shokat, K. M., Fisher, R. P., & Goga, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111317109 · Cited by 83
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 82
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 80
Jabbour-Leung, N. A., Chen, X., Bui, T. N., Jiang, Y., Yang, D., Vijayaraghavan, S., McArthur, M. J., Hunt, K. K., & Keyomarsi, K. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0519 · Cited by 76
Yu, M., Zhan, Q., & Finn, O. J. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00026-3 · Cited by 74
The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27
Wingate, H. F., Zhang, N., McGarhen, M. J., Bedrosian, I., Harper, J. W., & Keyomarsi, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409789200 · Cited by 72
Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
Lin, Z. P., Zhu, Y.-L., & Ratner, E. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00303 · Cited by 68
Huskey, N. E., Guo, T., Evason, K. J., Momčilović, O., Pardo, D. M., Creasman, K. J., Judson, R. L., Blelloch, R. H., Oakes, S. A., Hebrok, M., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.01.019 · Cited by 67
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
Iwai, K., Nambu, T., Dairiki, R., Ohori, M., Yu, J., Burke, K. E., Gotou, M., Yamamoto, Y., Ebara, S., Shibata, S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav3660 · Cited by 67
Beale, G., Haagensen, E. J., Thomas, H. D., Wang, L.-Z., Revill, C., Payne, S. L., Golding, B. T., Hardcastle, I. R., Newell, D. R., Griffin, R. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.238 · Cited by 66
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi, A., Caramuta, S., Seashore-Ludlow, B. A., Boström, J., Robinson, J. L., Edfors, F., Tuominen, R., Kemper, K., Krijgsman, O., Peeper, D. S., et al. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177858 · Cited by 66
Caruso, J. A., Duong, M. T., Carey, J. P. W., Hunt, K. K., & Keyomarsi, K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1235 · Cited by 64
Desai, B. M., Villanueva, J., Nguyen, T.-T. K., Lioni, M., Xiao, M., Kong, J., Krepler, C., Vultur, A., Flaherty, K. T., Nathanson, K. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059588 · Cited by 63
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 62
Cyclin E Deregulation and Genomic Instability
Teixeira, L. K., & Reed, S. I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6955-0_22 · Cited by 61
Vella, L. A., Yu, M., Fuhrmann, S. R., El-Amine, M., Epperson, D. E., & Finn, O. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903225106 · Cited by 59
Targeting DNA Replication before it Starts
Rodríguez‐Acebes, S., Proctor, I., Loddo, M., Wollenschlaeger, A., Rashid, M., Falzon, M., Prevost, A. T., Sainsbury, R., Stoeber, K., & Williams, G. H. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100421 · Cited by 58
McLaughlin, R. P., He, J., van der Noord, V. E., Redel, J., Foekens, J. A., Martens, J. W. M., Smid, M., Zhang, Y., & van de Water, B. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1161-9 · Cited by 58
Kinase-independent function of E-type cyclins in liver cancer
Geng, Y., Michowski, W., Chick, J. M., Wang, Y. E., Jecrois, M., Sweeney, K. E., Liu, L., Han, R. C., Ke, N., Zagożdżon, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711477115 · Cited by 52
Regulation of the initiation of DNA replication in human cells
Moiseeva, T. N., & Bakkenist, C. J. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.09.003 · Cited by 51
Li, B., Zhu, H., Song, G., Cheng, J., Li, C., Zhang, Y., & Zhao, P. (2019) · Oncology Letters · doi:10.3892/ol.2019.10847 · Cited by 50
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Rao, S. S., Stoehr, J. R., Đokić, D., Wan, L., Decker, J. T., Konopka, K. E., Thomas, A. L., Wu, J., Kaklamani, V., Shea, L. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20202 · Cited by 47
Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell Lymphomas
Faber, A. C., & Chiles, T. C. (2007) · Cell Cycle · doi:10.4161/cc.6.23.4994 · Cited by 46
Cyclin B1 Suppresses Colorectal Cancer Invasion and Metastasis by Regulating E-Cadherin
Fang, Y., Liang, X. H., Jiang, W., Li, J., Xu, J., & Cai, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126875 · Cited by 45
A novel landscape of nuclear human CDK2 substrates revealed by in situ phosphorylation
Chi, Y., Carter, J. H., Swanger, J., Mazin, A. V., Moritz, R. L., & Clurman, B. E. (2020) · Science Advances · doi:10.1126/sciadv.aaz9899 · Cited by 45
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma
Ciznadija, D., Liu, Y., Pyonteck, S. M., Holland, E. C., & Koff, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1031 · Cited by 44
Karsunky, H., Geisen, C., Schmidt, T., Haas, K., Zevnik, B., Gau, E., & Möröy, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203205 · Cited by 44
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth
Pestell, T. G., Jiao, X., Kumar, M., Peck, A. R., di Prisco, M., Deng, S., Li, Z., Ertel, A., Casimiro, M. C., Ju, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19953 · Cited by 44
Yang, C.-C., Kato, H., Shindo, M., & Masai, H. (2019) · eLife · doi:10.7554/elife.50796 · Cited by 43
Natoni, A., Murillo, L. S., Kliszczak, A. E., Catherwood, M. A., Montagnoli, A., Afshin Samali, A., O'Dwyer, M. E., & Santocanale, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1119 · Cited by 42
Mazumder, S., Plesca, D. C., & Almasan, A. (2007) · Cell Cycle · doi:10.4161/cc.6.12.4432 · Cited by 41
Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1
Caldon, C. E., Sergio, C. M., Burgess, A., Deans, A. J., Sutherland, R. L., & Musgrove, E. A. (2013) · Cell Cycle · doi:10.4161/cc.23512 · Cited by 38
Drug design with Cdc7 kinase: a potential novel cancer therapy target
Masai, H. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s4303 · Cited by 34
CDK4/6 Inhibitors: What Is the Best Cocktail?
Malumbres, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2177 · Cited by 34
Loss of p27Kip1 cooperates with cyclin E in T-cell lymphomagenesis
Geisen, C., Karsunky, H., Yücel, R., & Möröy, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206340 · Cited by 30
Cyclin A2, a novel regulator of EMT
Bendris, N., Cheung, C., Leong, H. S., Lewis, J. D., Chambers, A. F., Blanchard, J. M., & Lemmers, B. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1654-8 · Cited by 25
Lee, Y., Lee, C. E., Oh, S., Kim, H.-D., Lee, J., Kim, S. B., & Kim, S. B. (2020) · Cancers · doi:10.3390/cancers12061418 · Cited by 25
Santala, S., Talvensaari‐Mattila, A., Soini, Y., Honkavuori-Toivola, M., & Santala, M. (2014) · Tumor Biology · doi:10.1007/s13277-014-1703-9 · Cited by 21
Moore, N. L. T., Edwards, D. P., & Weigel, N. L. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.09.009 · Cited by 20
Cyclin A is a reliable proliferation marker in endometrial cancer cell lines.
Horie, K., Yamamoto, H., Karube, K., Takebayashi, K., Yoshino, H., Yoshioka, H., & Watanabe, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10135 · Cited by 16
Li, W., Zhao, X., Shang, S., Shen, H., & Chen, X. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009615666150212112753 · Cited by 14
The requirement for cyclin E in c-Myc overexpressing breast cancers
Zhou, Y., Geng, Y., Zhang, Y., Zhou, Y., Chu, C., Sharma, S., Fassl, A., Butter, D., & Siciński, P. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1804720 · Cited by 10
Cited by
ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways
de Almeida, A. J. P. O., de Oliveira, J. C. P. L., da Silva Pontes, L. V., de Souza Júnior, J. F., Gonçalves, T. A. F., Dantas, S. H., de Almeida Feitosa, M. S., Silva, A. O., & de Medeiros, I. A. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1225578 · Cited by 474
Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability
Fagundes, R., & Teixeira, L. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.774845 · Cited by 276
Computational challenges of cell cycle analysis using single cell transcriptomics
Chervov, A., & Zinovyev, A. (2022) · arXiv · doi:10.48550/arxiv.2208.05229 · Cited by 4
Metadata
- Authors
- Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 39
- Issue
- 6
- Pages
- 759-778
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3156721991
- Cited by
- 564
- References
- 163
- FWCI
- 29.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.